Abbott, the global healthcare leader, and Novo, a global leader in treatments for serious chronic diseases, have announced an expanded strategic collaboration to increase access to originator semaglutide for people living with type 2 diabetes across Asia Pacific.
Under the agreement, Abbott will commercialise Plosbrio® (semaglutide), developed and manufactured by Novo, across Singapore and other Asia Pacific countries, expanding access to an evidence-based diabetes treatment in a region facing a rapidly growing diabetes burden.
Plosbrio® is a second brand of Ozempic®, one of the world's most prescribed GLP-1 RA (receptor agonist) molecules.
The agreement represents a new regional approach to broadening access to semaglutide in Asia Pacific. It combines Novo's leadership in diabetes care medicines and GLP-1 therapies with Abbott's extensive healthcare and commercial footprint across the region, as well as Abbott's broad leadership across the diabetes care continuum, including medicines, diagnostics, continuous glucose monitoring and diabetes-specific nutrition.
Plosbrio® is indicated as an adjunct to diet and exercise for adults with type 2 diabetes. Semaglutide, the molecule in Plosbrio®, has demonstrated significant HbA1c reduction, weight-loss benefits, and proven reduced risk of cardiovascular and kidney events in people with type 2 diabetes.
This agreement builds on a growing collaboration between the two companies, including Abbott's commercialisation of Extensior®, another second brand of semaglutide Ozempic® for adults with type 2 diabetes in India.
